Actionable news
All posts from Actionable news
Actionable news in NKTR: Nektar Therapeutics,

Trade Of The Week

Nektar Therapeutics (NKTR) shares have been consolidating in a three-point range since early April and name with notable bullish flow in open interest including 5,000 of the August $22 and $25 calls bought in April and 700 November $20 calls bought in May.

The $3.03B biotech is not yet profitable and trades 23X sales and 8.5X cash with 18% sales growth the last five years. NKTR expects to see 18.3% Y/Y revenue growth in 2018 and targeting $375-$400M by 2021. NKTR has a deep pipeline of therapies in immune-oncology, pain management, immunology, and cancer chemotherapy. Their treatment NKTR-181 has...